Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers.
Dybowski JN, Riemenschneider M, Hauke S, Pyka M, Verheyen J, Hoffmann D, Heider D.
BioData Min. 2011 Nov 14;4:26.
Related citations
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A, van Maarseveen NM, Pokorná J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M.
Retrovirology. 2011 Aug 24;8:70.
Predicting Bevirimat resistance of HIV-1 from genotype.
Heider D, Verheyen J, Hoffmann D.
BMC Bioinformatics. 2010 Jan 20;11:37.
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.
Retrovirology. 2011 Dec 7;8:101.
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA, Gibbs CS, Miller MD.
Antimicrob Agents Chemother. 2010 Jun;54(6):2345-53. Epub 2010 Mar 22.
The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
Yebra G, Holguín A.
Antivir Ther. 2008;13(8):1083-5.
Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
Martin DE, Salzwedel K, Allaway GP.
Antivir Chem Chemother. 2008;19(3):107-13. Review.
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL.
Drugs. 2003;63(8):769-802. Review.
Maturation inhibitors: a new therapeutic class targets the virus structure.
Salzwedel K, Martin DE, Sakalian M.
AIDS Rev. 2007 Jul-Sep;9(3):162-72. Review.
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K.
Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.
Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B, Murphy RL, Katlama C.
Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. Epub 2007 Jul 16.
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE.
PLoS One. 2007 Nov 28;2(11):e1251.
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M.
AIDS. 2010 Mar 13;24(5):669-73.
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR.
PLoS Med. 2006 Sep;3(9):e356.
Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL.
APMIS Suppl. 2003;(114):1-37. Review.
Novel targets for antiretroviral therapy: clinical progress to date.
Dau B, Holodniy M.
Drugs. 2009;69(1):31-50. doi: 10.2165/00003495-200969010-00003. Review.
Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy.
Altmann A, Rosen-Zvi M, Prosperi M, Aharoni E, Neuvirth H, Schülter E, Büch J, Struck D, Peres Y, Incardona F, Sönnerborg A, Kaiser R, Zazzi M, Lengauer T.
PLoS One. 2008;3(10):e3470. Epub 2008 Oct 21.
In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1.
Knapp DJ, Harrigan PR, Poon AF, Brumme ZL, Brockman M, Cheung PK.
J Clin Microbiol. 2011 Jan;49(1):201-8. Epub 2010 Nov 17.
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
Acc Chem Res. 2008 Jan;41(1):78-86. Epub 2007 Aug 28. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on